Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors

[1]  X. Thomas,et al.  Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. , 2003, Leukemia research.

[2]  M. Kalaycio,et al.  Treatment of refractory and relapsed acute myelogenous leukemia , 2002, Expert review of anticancer therapy.

[3]  H. Dombret,et al.  Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial) , 1999, Leukemia.

[4]  P. Sonneveld,et al.  Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Cony-Makhoul,et al.  Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. , 1996, Leukemia.

[6]  R. Zittoun,et al.  Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group , 1996, Annals of Hematology.

[7]  P. Fenaux,et al.  Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  X. Thomas,et al.  Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Lister,et al.  The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period , 1993, British journal of haematology.

[10]  L. Zwelling,et al.  Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. , 1993, Blood.

[11]  C. Sebban,et al.  Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. , 1992, Leukemia.

[12]  M. Schell,et al.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Marcus,et al.  Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Mandelli,et al.  Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Fenaux,et al.  Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. , 1991, Blood.

[16]  M. Labopin,et al.  Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide , 1991 .

[17]  M. Sanz,et al.  A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Herzig,et al.  High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. , 1990, Blood.

[19]  F. Mandelli,et al.  BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. , 1990, Blood.

[20]  R. Donehower,et al.  In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. , 1989, Blood.

[21]  T. Lipp,et al.  Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Sullivan,et al.  The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. , 1987, Bone marrow transplantation.

[23]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[24]  J. Karp,et al.  A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. , 1980, Blood.

[25]  H. Preisler.  Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.

[26]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.